½ÃÀ庸°í¼­
»óǰÄÚµå
1716724

ÀϹÝÀǾàǰ(OTC) ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)

Over the Counter (OTC) Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ÀϹÝÀǾàǰ ½ÃÀåÀº 2024³â 1,800¾ï ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç, 2025³âºÎÅÍ 2034³â±îÁö ¿¬Æò±Õ 5.4%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

¼ÒºñÀÚµéÀÇ °Ç°­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÛÀº Áúº´¿¡µµ Àû±ØÀûÀ¸·Î ´ëóÇÏ´Â °æÇâÀÌ ³ô¾ÆÁü¿¡ µû¶ó, OTC ÀǾàǰÀº ºü¸¥ ¿ÏÈ­¿Í ºñ¿ë È¿À²ÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ´Â ¼Ö·ç¼ÇÀ¸·Î ºü¸£°Ô ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¾à±¹, ½´ÆÛ¸¶ÄÏ, ¿Â¶óÀÎ Ç÷§Æû, ÆíÀÇÁ¡ µî¿¡¼­ OTC Á¦Ç°À» ½±°Ô ±¸ÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ ¼ÒºñÀڴ ó¹æÀü ¾øÀ̵µ ÇÊ¿äÇÑ ÀǾàǰÀ» ½±°Ô ±¸ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ºü¸¥ ¿ëÇØ Á¤Á¦, ÇâÀÌ ³ª´Â ½Ã·´ µî ÀǾàǰÀÇ Á¦ÇüÀÌ °è¼Ó ¹ßÀüÇϸ鼭 »ç¿ëÀÚÀÇ ÆíÀǼº°ú ¼øÀÀµµ°¡ Çâ»óµÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Over the Counter(OTC)Drugs Market-IMG1

Àü ¼¼°è ±ÔÁ¦ ±â°üÀº ¾ö°ÝÇÑ Ç°Áú °Ë»ç¿Í °¡À̵å¶óÀÎÀ» º¸ÀåÇÔÀ¸·Î½á ÀÏ»óÀûÀÎ °Ç°­ ¹®Á¦¿¡ ´ëÇÑ OTC ÀǾàǰ »ç¿ë¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ ³ôÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áºñ°¡ °è¼Ó »ó½ÂÇÔ¿¡ µû¶ó ¸¹Àº »ç¶÷µéÀÌ Àǻ縦 ¸¸³ªÁö ¾Ê°íµµ ÅëÁõ, °¨±â, ¼ÒÈ­±â Áúȯ, ÇǺΠ¿°Áõ°ú °°Àº ÀϹÝÀûÀÎ Áõ»óÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â OTC ÀǾàǰÀ» ¼±ÅÃÇÏ°Ô µÇ¸é¼­ Àüü ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °üÀýÅë, ¼ÒÈ­ºÒ·®, ¼ö¸éÀå¾Ö µî ¹Ýº¹µÇ´Â ¹®Á¦¿¡ ´ëÇÑ °£ÆíÇϰí Àú·ÅÇÑ ÇØ°áÃ¥À» ã´Â °í·ÉÈ­ »çȸ°¡ OTC Á¦Ç°¿¡ ´ëÇÑ Àå±âÀûÀÎ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¹æÀû °Ç°­°ü¸®¿Í À£´Ï½º º¸ÃæÁ¦¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼ÒºñÀÚÀÇ ±¸¸Å Çൿ¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ¸¹Àº »ç¶÷µéÀÌ °Ç°­°ú À£ºùÀ» À¯ÁöÇϱâ À§ÇØ ºñŸ¹Î, ¹Ì³×¶ö, Çãºê º¸ÃæÁ¦¸¦ ÀÏ»ó »ýȰÀÇ ÀϺηΠ¹Þ¾ÆµéÀ̰í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 1,800¾ï ´Þ·¯
¿¹»ó ±Ý¾× 3,023¾ï ´Þ·¯
CAGR 5.4%

ÀÇ»çÀÇ Ã³¹æÀüÀÌ ÇÊ¿ä ¾ø´Â OTC ÀǾàǰÀº ¾ÈÀü¼º, À¯È¿¼º ¹× ǰÁúÀ» º¸ÀåÇϱâ À§ÇØ º¸°Ç ´ç±¹¿¡ ÀÇÇØ ¾ö°ÝÇÏ°Ô ±ÔÁ¦µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰÀº Á¤Á¦, ¿¬°í, ½ºÇÁ·¹ÀÌ, ¿ë¾× µî ´Ù¾çÇÑ ÇüÅ·ΠÆÇ¸ÅµÇ°í ÀÖÀ¸¸ç, ÀϹÝÀûÀÎ °Ç°­ ¹®Á¦¸¦ °¡Á¤¿¡¼­ °ü¸®ÇÒ ¼ö ÀÖ´Â Æí¸®ÇÑ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº °¨±â¾à ¹× ±âħ¾à, ºñŸ¹ÎÁ¦ ¹× º¸ÃæÁ¦, ¼ÒÈ­ º¸Á¶Á¦, ÇǺΠġ·áÁ¦, ÁøÅëÁ¦, ¼ö¸é º¸Á¶Á¦ µî ´Ù¾çÇÑ Ä«Å×°í¸®·Î ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áß °¨±â¾à°ú ±âħ¾àÀº 2024³â 452¾ï ´Þ·¯¸¦ âÃâÇß½À´Ï´Ù. ƯÈ÷ ȯÀý±â¿¡´Â °¨±â³ª µ¶°¨°ú °°Àº È£Èí±âÁúȯÀÇ ¹ßº´·üÀÌ ³ô¾ÆÁö¸é¼­ ÃæÇ÷ ¿ÏÈ­Á¦³ª ±âħ ½Ã·´°ú °°Àº Áï°¢ÀûÀÎ È¿°ú°¡ ÀÖ´Â Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϱ⠶§¹®ÀÔ´Ï´Ù.

Á¤Á¦´Â Á¤È®ÇÑ º¹¿ë, ÆíÀǼº, ÅëÁõ, È£Èí±âÁúȯ, ±âŸ ±Þ¼º Áúȯ µîÀÇ Ä¡·á¿¡ »ç¿ëÇϱ⠽±±â ¶§¹®¿¡ ¿©ÀüÈ÷ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. Á¤Á¦ ±â¹ÝÀÇ OTC ½ÅÁ¦Ç°ÀÌ Áö¼ÓÀûÀ¸·Î Ãâ½ÃµÇ°í ÀÖ´Â °Íµµ ½ÃÀå Á¡À¯À²À» ³ôÀ̰í ÀÖ½À´Ï´Ù.

Áö¿ªº° ºÐ¼®¿¡ µû¸£¸é, ¹Ì±¹ OTC ÀǾàǰ ½ÃÀåÀº 2024³â 424¾ï ´Þ·¯ ±Ô¸ð·Î 2034³â±îÁö ¿¬Æò±Õ 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ÀÇ ÅºÅºÇÑ Á¦¾à ȯ°æ, ´ë±Ô¸ð R&D ÅõÀÚ, ¼¿ÇÁ Äɾ ´ëÇÑ °ü½É Áõ°¡, Á¶±â Ä¡·á ¹× ¿¹¹æ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¾÷°è »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¿ÇÁ ¸ÞµðÄÉÀ̼ǰú Áúº´ °ü¸®¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀÎ½Ä È®»ê
      • OTC ÀǾàǰÀ¸·ÎÀÇ À̵¿À¸·Î À̾îÁö´Â 󹿾àÀÇ °íºñ¿ë
      • OTC ÀǾàǰ ½ÂÀο¡ ´ëÇÑ À¯¸®ÇÑ ±ÔÁ¦ Áö¿ø
      • Á¦Ç° ÀÔ¼ö ¿ëÀ̼º È®´ë
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¡¤°úÁ¦
      • ¿À¿ëÀ̳ª ¾à¹° ³²¿ë¿¡ ´ëÇÑ ¿ì·Á
      • ¾à¿¡ ÀÇÇÑ ºÎÀÛ¿ëÀ̳ª »óÈ£ÀÛ¿ëÀÇ °¡´É¼º
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ó¹æ¾à¿¡¼­ ºñ󹿾àÀ¸·ÎÀÇ ±³Ã¼ ¸®½ºÆ®
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ½ÃÀå ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÀǾàǰ Ä«Å×°í¸®º°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • °¨±â¾à¡¤±âħ¾à
  • ºñŸ¹Î¡¤º¸ÃæÁ¦
  • ¼ÒÈ­±â¡¤Àå³» Ä¡·áÁ¦
  • ÇǺΠġ·áÁ¦
  • ÁøÅëÁ¦
  • ¼ö¸é º¸Á¶Á¦
  • ±âŸ ÀǾàǰ Ä«Å×°í¸®

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Á¦Á¦ À¯Çüº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • Á¤Á¦
  • ¾×Á¦
  • ¿¬°íÁ¦
  • ½ºÇÁ·¹ÀÌÁ¦

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : À¯Åë ä³Îº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ¿Â¶óÀΠä³Î
  • ¿ÀÇÁ¶óÀΠä³Î
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ±âŸ ¿ÀÇÁ¶óÀΠä³Î

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®

Á¦9Àå ±â¾÷ °³¿ä

  • Abbott
  • Alkem Laboratories
  • Aytu Biopharma(Aytu Consumer Health)
  • Bayer AG
  • Cipla
  • Dr. Reddy's Laboratories
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals
  • Haleon
  • Johnson & Johnson Services
  • Perrigo Company
  • Pfizer
  • Piramal Enterprises
  • Reckitt Benckiser Group
  • Sanofi
  • Sun Pharmaceuticals
  • Teva Pharmaceutical Industries
  • The Blackstone Group(Alinamin Pharmaceutical)
  • Viatris
ksm 25.05.22

The Global Over the Counter Drugs Market was valued at USD 180 billion in 2024 and is projected to expand at a 5.4% CAGR between 2025 and 2034, driven largely by a rising consumer preference for self-medication and increasing demand for accessible healthcare solutions. As consumers become more health-conscious and proactive in managing minor ailments, OTC drugs are quickly emerging as a go-to solution for quick relief and cost-effective treatment options. The widespread availability of OTC products in pharmacies, supermarkets, online platforms, and convenience stores is making it easier for consumers to access essential medications without a prescription. In addition, ongoing advancements in drug formulations, such as fast-dissolving tablets and flavored syrups, are enhancing user convenience and compliance, fueling market growth even further.

Over the Counter (OTC) Drugs Market - IMG1

Regulatory bodies across the globe are also playing a crucial role by ensuring stringent quality checks and guidelines, which boost consumer confidence in using OTC medications for everyday health concerns. As healthcare costs continue to rise, many individuals are opting for OTC options to manage common conditions like pain, colds, digestive issues, and skin irritations without the need for physician visits, thereby contributing to overall market expansion. Furthermore, an aging population seeking easy and affordable solutions for recurring issues like joint pain, digestive discomfort, and sleep disorders is supporting long-term demand for OTC products. The growing trend toward preventive healthcare and wellness supplements is also influencing consumer purchasing behavior, with many people adopting vitamins, minerals, and herbal supplements as part of their daily routines to maintain health and well-being.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$180 Billion
Forecast Value$302.3 Billion
CAGR5.4%

OTC drugs, which do not require a doctor's prescription, are carefully regulated by health authorities to ensure their safety, efficacy, and quality. These medications are available in diverse forms, such as tablets, ointments, sprays, and solutions, offering users convenient options for managing common health issues at home. The market is segmented into various categories, including cold and cough remedies, vitamins and supplements, digestive aids, skin treatments, pain relievers, sleeping aids, and others. Among these, cold and cough remedies generated USD 45.2 billion in 2024, as the rising incidence of respiratory illnesses like colds and flu, particularly during seasonal transitions, drives demand for quick-relief products such as decongestants and cough syrups.

When looking at product formulation, tablets dominated the OTC market with USD 85.9 billion in 2024, as they remain the preferred choice due to precise dosing, convenience, and ease of use for treating conditions such as pain, respiratory issues, and other acute ailments. The consistent launch of new tablet-based OTC products continues to boost their market share.

In regional analysis, the U.S. OTC Drugs Market accounted for USD 42.4 billion in 2024 and is anticipated to grow at a 4.8% CAGR through 2034. The country's robust pharmaceutical landscape, significant R&D investments, and rising consumer inclination toward self-care are propelling market growth alongside growing awareness around early treatment and preventive healthcare solutions.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing consumer awareness for self-medication and disease management
      • 3.2.1.2 High cost of prescription drugs leading to shift towards OTC drugs
      • 3.2.1.3 Favorable regulatory support for OTC drug approvals
      • 3.2.1.4 Expanding product accessibility
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Concern towards misuse or drug abuse
      • 3.2.2.2 Potential side effects and interactions due to medication
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Prescription to nonprescription switch list
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Category, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Cold and cough remedies
  • 5.3 Vitamins and supplements
  • 5.4 Digestive and intestinal remedies
  • 5.5 Skin treatment
  • 5.6 Analgesics
  • 5.7 Sleeping aids
  • 5.8 Other drug categories

Chapter 6 Market Estimates and Forecast, By Formulation Type, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Tablets
  • 6.3 Liquids
  • 6.4 Ointments
  • 6.5 Sprays

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Online channels
  • 7.3 Offline channels
    • 7.3.1 Hospital pharmacies
    • 7.3.2 Retail pharmacies
    • 7.3.3 Other offline channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 India
    • 8.4.3 Japan
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 Alkem Laboratories
  • 9.3 Aytu Biopharma (Aytu Consumer Health)
  • 9.4 Bayer AG
  • 9.5 Cipla
  • 9.6 Dr. Reddy's Laboratories
  • 9.7 GlaxoSmithKline Plc
  • 9.8 Glenmark Pharmaceuticals
  • 9.9 Haleon
  • 9.10 Johnson & Johnson Services
  • 9.11 Perrigo Company
  • 9.12 Pfizer
  • 9.13 Piramal Enterprises
  • 9.14 Reckitt Benckiser Group
  • 9.15 Sanofi
  • 9.16 Sun Pharmaceuticals
  • 9.17 Teva Pharmaceutical Industries
  • 9.18 The Blackstone Group (Alinamin Pharmaceutical)
  • 9.19 Viatris
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦